Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Celtic Pharmaceutical Holdings L.P. today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept with Avastin.

22 Oct 2010

Mirna announces USPTO allows claims to therapeutic application of let-7 miRNA

Mirna Therapeutics, Inc. announced today that the USPTO has allowed claims related to the therapeutic application of let-7 in the regulation of oncogenes. The claims derive from a patent application that was submitted by Yale University and exclusively licensed to Mirna related to the pioneering work of Dr. Frank Slack, Professor of Molecular, Cellular & Developmental Biology at Yale University in New Haven, CT.

20 Oct 2010

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG in pancreatic cancer, the company announced today.

24 Sep 2010

Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.

20 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

Enlyton publishes cancer imaging study results of colorectal cancer

Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton's antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer.

13 Sep 2010

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

RTI Biologics, Zimmer ink global distribution agreement for dental biologic implants

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, announced today the signing of an exclusive, 10-year distribution agreement with Zimmer Dental Inc. for biologic implants for the dental market worldwide.

8 Sep 2010

RTI, Medtronic take several steps to continuously improve their relationship

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, in response to inquiries regarding Medtronic's announced acquisition of Osteotech stated today that the relationship between Medtronic and RTI Biologics continues to be strong, with no changes near-term.

18 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

RTI Biologics second-quarter worldwide revenues in sports medicine increase 14%

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, reported operating results for the second quarter ended June 30, 2010.

5 Aug 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

19 Jul 2010

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.

15 Jul 2010

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.

15 Jul 2010

Preclinical results of TH-302 presented at AACR Translational Cancer Medicine Meeting

Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.

13 Jul 2010

Researchers demonstrate that MSNs can effectively suppress tumors in mice

The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.

12 Jul 2010

Novel molecular pathway that regulates invasive growth, metastasis in ER-positive breast cancer discovered

A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.

6 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010